Volume 2 Issue 3
Exhaled nitric oxide (eNO) in the evaluation and treatment of mild intermittent asthma
Andrew Ayars, MD*, Stephen Tilles, MD, Leonard Altman, MD
Asthma is traditionally diagnosed and managed based on clinical history and pulmonary function testing and in recent years there has been an effort to develop biomarkers to aid in the diagnosis and management. Exhaled nitric oxide (eNO) is a biomarker that is gaining popularity for use in clinical practice. In this study we evaluated the utility of this biomarker in the diagnosis and management of asthma by comparing eNO with clinical history, asthma control test (ACT), and FEV1% in 10 subjects with mild intermittent asthma.
Targeting the PAF:PAF Receptor Interaction to Manage PMN Recruitment to the Lung of Smokers
John O. Marentette, Janhavi Sharma and Jane McHowat*
Cigarette smoking is associated with a high degree of mortality and morbidity and is associated with damage to almost every organ in the body, particularly the lungs. Smokers are at increased risk for pulmonary diseases such as chronic obstructive pulmonary disease (COPD) which involves a robust migration of leukocytes. We have demonstrated previously that adherence of polymorphonuclear leukocytes (PMN) to lung endothelial cells exposed to cigarette smoke extract (CSE) is mediated via inhibition of platelet-activating factor acetylhydrolase (PAF-AH) activity, leading to PAF accumulation.